Profile data is unavailable for this security.
About the company
Deva Holding AS is a Turkey-based pharmaceutical company that is primarily engaged in the production and marketing of finished pharmaceutical products, pharmaceutical ingredients and veterinary products, as well as animal health products, among others. The Company has four production facilities in Turkey. Its production facilities include the Tokapi, Cerezkoy I, Cerezkoy II and Kartepe production plants. The Company’s product portfolio comprises 73 drugs, which are available on the market in 177 various forms. It offers products, such as Azitro, Alemax, Cefax, Inhibace, Imatis, Hydrea, Kardozin, Kristapen, Magcar, Magnesie Calcinee, Nostil, Oceral, Remidon, Prolixin and Quet, among others. The Company has two subsidiaries, namely Vetaa Veteriner ve Tarim Ilaclari A.S. and Deva Holding NZ Ltd.
- Revenue in TRY (TTM)11.45bn
- Net income in TRY4.03bn
- Incorporated1958
- Employees2.94k
- LocationDeva Holding ASKucukcekmeceISTANBUL 34303TurkeyTUR
- Phone+90 2 126929292
- Fax+90 2 126970208
- Websitehttps://www.deva.com.tr
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Standard Chem & Pharm Co Ltd | 7.06bn | 911.43m | 12.41bn | 1.13k | 13.63 | 2.00 | 7.36 | 1.76 | 4.78 | 4.78 | 36.97 | 32.57 | 0.5753 | 2.31 | 6.33 | -- | 10.47 | 9.68 | 20.28 | 17.61 | 43.86 | 43.75 | 18.20 | 17.02 | 1.49 | -- | 0.0856 | 60.34 | 6.64 | 11.80 | 2.39 | 17.40 | 29.97 | 12.47 |
| Adimmune Corp | 1.77bn | -648.75m | 12.42bn | 564.00 | -- | 2.27 | -- | 7.03 | -1.44 | -1.44 | 3.93 | 11.92 | 0.1848 | 1.25 | 4.04 | -- | -8.27 | 0.6867 | -10.19 | 0.7739 | 27.82 | 30.11 | -44.75 | 3.04 | 1.99 | -24.75 | 0.3284 | 32.80 | -20.72 | 16.77 | -319.91 | -- | 38.05 | -- |
| Niox Group PLC | 1.67bn | 431.93m | 12.65bn | 85.00 | 31.03 | 3.07 | 20.01 | 7.56 | 0.0211 | 0.0238 | 0.0819 | 0.2136 | 0.3874 | 2.31 | 6.13 | 432,941.20 | 10.00 | -2.41 | 10.57 | -2.90 | 72.01 | 70.87 | 25.82 | -11.46 | 3.99 | -- | 0.013 | -- | 17.57 | -5.29 | -32.62 | -- | -5.59 | -- |
| SMS Pharmaceuticals Ltd | 3.02bn | 232.86m | 12.75bn | 1.20k | 54.60 | -- | 35.06 | 4.22 | 6.75 | 6.75 | 87.48 | -- | -- | -- | -- | 6,168,549.00 | -- | 5.43 | -- | 7.33 | 30.12 | 33.30 | 7.69 | 7.87 | -- | 4.21 | -- | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Formosa Laboratories Inc | 5.01bn | 273.13m | 12.76bn | 480.00 | 47.07 | 1.59 | 19.91 | 2.55 | 2.11 | 2.11 | 38.90 | 62.49 | 0.3479 | 1.49 | 4.42 | -- | 0.7067 | 2.68 | 0.9689 | 3.61 | 44.30 | 35.40 | 2.03 | 8.75 | 1.18 | 0.8922 | 0.3155 | 27.38 | 15.80 | 10.16 | -69.16 | -6.52 | -11.60 | 32.22 |
| Deva Holding AS | 11.45bn | 4.03bn | 12.87bn | 2.94k | 3.19 | 0.7785 | 2.51 | 1.12 | 20.17 | 20.17 | 57.25 | 82.66 | 0.6671 | 2.17 | 7.02 | 3,937,134.00 | 23.50 | 14.23 | 36.20 | 20.90 | 40.49 | 41.85 | 35.23 | 24.77 | 1.14 | -- | 0.2565 | 2.36 | 30.04 | 61.21 | 297.79 | 90.10 | 69.34 | -- |
| Shanghai Shenqi Pharmactcl Inv Mgt CoLtd | 10.87bn | 290.90m | 12.99bn | 1.43k | 42.11 | 1.20 | -- | 1.19 | 0.1237 | 0.1237 | 4.36 | 4.34 | 0.7002 | 5.48 | 5.73 | 1,574,780.00 | 1.95 | -0.6002 | 2.48 | -0.7417 | 45.89 | 56.64 | 2.79 | -0.9128 | 2.50 | 23.18 | 0.1488 | -- | -2.00 | 4.79 | 17.41 | -11.68 | -25.97 | -- |
| Solara Active Pharma Sciences Ltd | 5.31bn | -2.29bn | 13.16bn | 2.16k | -- | -- | -- | 2.48 | -143.75 | -143.75 | 334.17 | -- | -- | -- | -- | 6,030,149.00 | -- | -2.44 | -- | -3.84 | 37.34 | 41.16 | -43.17 | -4.49 | -- | -1.57 | -- | -- | -10.73 | -1.45 | -2,458.12 | -- | -4.81 | -- |
| Celon Pharma SA | 1.87bn | -405.81m | 13.31bn | 568.00 | -- | 3.08 | 180.67 | 7.12 | -0.8908 | -0.8908 | 4.11 | 9.00 | 0.3592 | 2.21 | 5.21 | 400,898.70 | -7.79 | -2.24 | -9.03 | -2.57 | 70.12 | 70.71 | -21.69 | -7.79 | 2.27 | -64.27 | 0.0321 | -- | 11.29 | 11.57 | 28.40 | -- | -13.42 | -19.73 |
Data as of Sep 20 2024. Currency figures normalised to Deva Holding AS's reporting currency: Turkish Lira TRY
0.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 533.20k | 0.27% |
| Amundi Asset Management SA (Investment Management)as of 04 Sep 2024 | 33.03k | 0.02% |
| Dimensional Fund Advisors Ltd.as of 30 Jun 2024 | 31.57k | 0.02% |
| Legal & General Investment Management Ltd.as of 31 Jul 2024 | 12.25k | 0.01% |
| Handelsbanken Fonder ABas of 31 Aug 2024 | 9.86k | 0.01% |
| DBX Advisors LLCas of 05 Sep 2024 | 5.13k | 0.00% |
| DFA Australia Ltd.as of 31 Jul 2024 | 1.96k | 0.00% |
| Goldman Sachs Asset Management LPas of 06 Sep 2024 | 1.16k | 0.00% |
| AK Asset Management ASas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 18 Sep 2024Source: FactSet Research Systems Inc.
